Chemistry:Flezurafenib

From HandWiki

Flezurafenib is an investigational new drug designed as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor which is being evaluated for the treatment of cancer. Developed by Jazz Pharmaceuticals, this novel therapeutic agent is currently being explored for its efficacy against solid tumors and hematological malignancies harboring oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway.[1][2] As of January 2025, flezurafenib has reached Phase 1 clinical trials, where it is being evaluated for the treatment of advanced cancers and advanced malignant solid neoplasms.[1]

References

  1. ↑ 1.0 1.1 "JZP-815". PatSnap. https://synapse.patsnap.com/drug/86d0520bad8b482b92a1a33560125aea. 
  2. ↑ "The role of CRAF in cancer progression: from molecular mechanisms to precision therapies". Nature Reviews. Cancer 24 (2): 105–122. February 2024. doi:10.1038/s41568-023-00650-x. PMID 38195917. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Flezurafenib&oldid=4032051"